Jakubowiak, A J <br/><br/>
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.  [electronic resource] 

 -  Leukemia  Dec 2013 
 - 2351-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2013.152  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Chromosome Aberrations<br/>Female<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oligopeptides--therapeutic use<br/>Survival Analysis<br/>Treatment Outcome